31 jul: Correction to Singapore's 2Q Unemployment Rate Story
31 jul: Porsche Automobil Holding SE Profit up in First Half
31-07-2012 15:43:00

Auxilium Swings to First Quarterly Profit as Revenue Grows

Relateret indhold
16 jul - 
165 pct. i afkast i Bavarian Nordic på under ét år

By Chelsea Stevenson

Auxilium Pharmaceuticals Inc. (AUXL) posted its first profitable period in the second quarter as the specialty biopharmaceutical company saw double-digit revenue growth.

The company raised its revenue estimate for the year to $310 million to $332 million, from $293 million to $315 million.

The company's two main drugs are Xiaflex, which is currently allowed in the U.S. and Europe to treat some adults suffering from Dupuytren's contracture in a person's fingers that aren't able to fully extend from the palm, and testosterone replacement therapy Testim.

Auxilium plans to file with the U.S. Food and Drug Administration seeking approval for the potential use of Xiaflex in the treatment of certain penile dysfunction by the end of 2012. Analysts at RBC Capital Markets estimate the potential U.S. market for Peyronie's disease stands at more than $100 million. Meanwhile, the company has a deal with GlaxoSmithKline PLC (GSK) to promote Testim.

"For the remainder of 2012 and beyond, we will continue to focus on delivering excellence in commercial execution and we anticipate a positive additional impact from GlaxoSmithKline's efforts on Testim's growth," Chief Executive Adrian Adams said. "We also look forward to filing the sBLA [supplemental biologics license application] for Xiaflex for the treatment of Peyronie's disease by the end of the year as we seek to obtain FDA approval for this indication."

For the period ended June 30, Auxilium posted a profit of $7.7 million, of 16 cents a share, compared with a loss of $5.1 million, of 11 cents a share, in the year-ago period. The latest quarter includes stock-based compensation expense of $3.9 million, compared with a $4 million expense last year.

Revenue rose 19% to $78.2 million, primarily due to increases in U.S. sales where Xiaflex revenue climbed 21% and Testim revenue rose 26%.

Gross margin narrowed to 77% from 78% due to the high margin catch-up amortization that was recognized last year from Xiaflex.

By drug, Auxilium is raising its full-year guidance for global Testim revenue to $245 million to $255 million from $225 million to $235 million but cut its outlook for global Xiaflex revenue to $65 million to $77 million from $68 million to $80 million.

Shares closed Monday at $25.77 and were inactive premarket. The stock is up 44% in the past three months.

Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 31, 2012 09:43 ET (13:43 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Coloplast tager teten efter konkurrentnyt

23-04-2014 12:42:47
Et par lovende regnskaber fra et par af Coloplasts konkurrenter har medvirket til at sende medicoaktien til tops på det danske aktiemarked onsdag.Coloplast stig..

Aktier/middag: Investorerne slår koldt vand i blodet

23-04-2014 11:16:39
Efter en tirsdag hvor de danske og europæiske aktier blev sendt markant frem, er der mere ro på onsdag. Samlet bliver det til en lille nedgang for det toneangiv..

Aktier/tendens: Stigningerne vil løje af

23-04-2014 08:31:32
Efter en vild kursgalop tirsdag ventes det danske aktiemarked at slå over i skridt onsdag morgen.Futures på de europæiske aktiemarkeder ligger tæt på uændret, o..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Stigningerne vil løje af
2
Verdens største biotekselskab skuffer
3
Tirsdagens aktier: Genmab største vinder i massiv optur
4
Aktier/middag: Investorerne slår koldt vand i blodet
5
Største stigning i 14 år: Briter belønnes for tøj-entré i USA

Relaterede aktiekurser

GlaxoSmithKline PLC 1.646,00 0,4% Stigning i aktiekurs
GlaxoSmithKline PLC 55,43 0,2% Stigning i aktiekurs
Auxilium Pharmaceuticals.. 28,54 -0,6% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. april 2014 15:48:47
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140324.1 - EUROWEB6 - 2014-04-23 15:48:47 - 2014-04-23 15:48:47 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x